Log in
NASDAQ:KLDO

Kaleido Biosciences Stock Forecast, Price & News

$7.88
+0.26 (+3.41 %)
(As of 11/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$7.55
Now: $7.88
$8.00
50-Day Range
$5.77
MA: $7.36
$11.33
52-Week Range
$2.82
Now: $7.88
$11.89
Volume126,813 shs
Average Volume186,544 shs
Market Capitalization$283.54 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.44
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology. It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism; and a research collaboration with Janssen to prevent childhood-onset of atopic, immune, and metabolic conditions. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.04 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KLDO
CUSIPN/A
CIKN/A
Phone617 674 9000
Employees91

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$283.54 million
Next Earnings Date3/1/2021 (Estimated)
OptionableNot Optionable
$7.88
+0.26 (+3.41 %)
(As of 11/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KLDO News and Ratings via Email

Sign-up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kaleido Biosciences (NASDAQ:KLDO) Frequently Asked Questions

How has Kaleido Biosciences' stock been impacted by COVID-19?

Kaleido Biosciences' stock was trading at $5.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KLDO stock has increased by 42.2% and is now trading at $7.88.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Kaleido Biosciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Kaleido Biosciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Kaleido Biosciences?

Wall Street analysts have given Kaleido Biosciences a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kaleido Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Kaleido Biosciences' next earnings date?

Kaleido Biosciences is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Kaleido Biosciences
.

How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences, Inc. (NASDAQ:KLDO) announced its quarterly earnings results on Saturday, November, 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.62) by $0.03.
View Kaleido Biosciences' earnings history
.

What price target have analysts set for KLDO?

3 analysts have issued 12-month price objectives for Kaleido Biosciences' stock. Their forecasts range from $8.00 to $8.00. On average, they expect Kaleido Biosciences' stock price to reach $8.00 in the next year. This suggests a possible upside of 1.5% from the stock's current price.
View analysts' price targets for Kaleido Biosciences
.

Who are some of Kaleido Biosciences' key competitors?

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Stoke Therapeutics (STOK).

Who are Kaleido Biosciences' key executives?

Kaleido Biosciences' management team includes the following people:
  • Dr. Geoffrey von Maltzahn Ph.D., Co-Founder & Director (Age 39, Pay $35k)
  • Mr. Jerald Korn J.D., Gen. Counsel & Corp. Sec. (Age 41, Pay $464.81k)
  • Dr. Katharine Knobil M.D., Chief Medical Officer and Head of R&D (Age 56, Pay $668.03k)
  • Mr. Daniel L. Menichella B.A., M.B.A., Pres, CEO & Director (Age 61)
  • Mr. William E. Duke Jr., Chief Financial Officer (Age 48)
  • Dr. Johan van Hylckama Vlieg, Chief Scientific Officer
  • Ms. Susan Stewart J.D., Chief Regulatory Affairs Officer (Age 59)
  • Ms. Clare Fisher, Chief Bus. Officer

When did Kaleido Biosciences IPO?

(KLDO) raised $101 million in an initial public offering on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Kaleido Biosciences' stock symbol?

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

Who are Kaleido Biosciences' major shareholders?

Kaleido Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (0.47%), Charles Schwab Investment Management Inc. (0.27%), First Trust Advisors LP (0.11%), Squarepoint Ops LLC (0.07%), Morgan Stanley (0.03%) and BNP Paribas Arbitrage SA (0.01%). Company insiders that own Kaleido Biosciences stock include Kyriazi Theo Melas, Michael W Bonney, Ventures Fund Iv Gene Flagship and Ventures Fund V LP Flagship.
View institutional ownership trends for Kaleido Biosciences
.

Which institutional investors are selling Kaleido Biosciences stock?

KLDO stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, and State Street Corp.
View insider buying and selling activity for Kaleido Biosciences
.

Which institutional investors are buying Kaleido Biosciences stock?

KLDO stock was acquired by a variety of institutional investors in the last quarter, including Charles Schwab Investment Management Inc., First Trust Advisors LP, Squarepoint Ops LLC, and BNP Paribas Arbitrage SA. Company insiders that have bought Kaleido Biosciences stock in the last two years include Kyriazi Theo Melas, Michael W Bonney, Ventures Fund Iv Gene Flagship, and Ventures Fund V LP Flagship.
View insider buying and selling activity for Kaleido Biosciences
.

How do I buy shares of Kaleido Biosciences?

Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kaleido Biosciences' stock price today?

One share of KLDO stock can currently be purchased for approximately $7.88.

How big of a company is Kaleido Biosciences?

Kaleido Biosciences has a market capitalization of $283.54 million. Kaleido Biosciences employs 91 workers across the globe.

What is Kaleido Biosciences' official website?

The official website for Kaleido Biosciences is www.kaleido.com.

How can I contact Kaleido Biosciences?

The company can be reached via phone at 617 674 9000.

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.